A Study to Evaluate Efficacy of Investigational Product HeezOn Ultra -1/ HeezOn Ultra-2 on Male Sexual Health

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-31

Study Completion Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sexual function is a part of a normal healthy life and considered to be essential for mental, physical and marital well-being. Any derangement in normal function though is a distressing situation for the individual, is often not reported due to embarrassment or due to social stigma. Sexual disorders in men are categorized according to the stage of sexual response affected in terms of disorders of erectile function, ejaculatory function or libido, albeit there is considerable potential for overlap amongst the disorders. The use of current intervention has many side-effects and has been prohibited in cardiovascular condition and also to be taken with caution with other medical condition.

This has led to the development of multiple alternate therapies which are helpful for a limited number of cases but the major concern for all these therapies is their late onset of action and not having a sustained effect.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Study to Reduce Premature Ejaculation in Healthy Adult Men

NCT06571318

Premature Ejaculation Stress

NOT_YET_RECRUITING NA

Efficacy of Promescent Lidocaine Spray in Men With Premature Ejaculation

NCT02241460

Premature Ejaculation

UNKNOWN PHASE3

Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED)

NCT02495467

Erectile Dysfunction

COMPLETED PHASE2

Safety and Efficacy of YHD1023 in Erectile Dysfunction

NCT01423370

Erectile Dysfunction

COMPLETED PHASE2

Safety & Feasibility of Functional Electrical Stimulation for The Treatment of Premature Ejaculation

NCT03177226

Premature Ejaculation

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Enovate Biolife is trying to improvise further their already marketed product HeezOn® by adding new botanicals thus naming it HeezOn Ultra. HeezOn®has been studied on 148 subjects and has proven to be beneficial for subjects with mild to moderate ED. The previous study fell short to capture the data for subjects who were also suffering from PE and their overall quality of life-related to sexual health. Therefore, the trial is designed to study the speedy and sustained effect of the improvised formula on different aspects of sexual dysfunctions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Erectile Dysfunction Premature Ejaculation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HeezOn Ultra-1

HeezOn Ultra-1 includes ingredients like Shilajit, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.

Group Type ACTIVE_COMPARATOR

HeezOn Ultra-1

Intervention Type OTHER

HeezOn Ultra-2

HeezOn Ultra-2 includes ingredients like Arjuna, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.

Group Type ACTIVE_COMPARATOR

HeezOn Ultra-2

Intervention Type OTHER

Placebo

Placebo consists of Micro-crystalline Cellulose. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HeezOn Ultra-1

Intervention Type OTHER

HeezOn Ultra-2

Intervention Type OTHER

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Planning to have regular sexual activity (more than twice/ week).
2. Body Mass Index should be ≤ 29 kg/m2.
3. Subjects suffering from erectile dysfunction indicated by SHIMscore ≥ 12 and ≤ 16 for more than 3 months and less than 6 months.

OR
4. Subjects suffering from predominantly from premature ejaculation as indicated by PEDT score more than 11 for more than 3 months and less than 6 months.
5. Fasting blood sugar ≤ 120 mg/dl.
6. The subjects have to be non-smoker and non-alcoholic.

Exclusion Criteria

1. Subjects having SHIM score \<12 and \> 16.
2. Subjects suffering from premature ejaculation predominantly as indicated by PEDT score less than 11.
3. Subjects with major psychiatric disorders or severe systemic disorders
4. Subject having uncontrolled diabetes mellitus and hypertensive on active treatment
5. Subjects having history of male sexual dysfunction more than six months in diabetic subjects.
6. Anatomical deformity of the penis such as severe penile fibrosis or Peyronie's disease or phimosis.
7. Subjects detected with HIV and suffering from AIDS.
8. Has an abnormal thyroid stimulating hormone (TSH) level lower than 30% of lower limit normal or more than 30% of upper limit normal.
9. Has erectile dysfunction caused by neurological or endocrine factors such as hyper-prolactinemia.
10. Subjects with history of major systemic disorders.
11. Subject with history of drug abuse.
12. Subjects using medications known to cause sexual dysfunction (cimetidine, spironolactone, thiazides, adrenergic blockers, antidepressants etc.)
13. Subject has participated in any clinical trial within last 30 days.
14. Subjects not ready to sign the consent \& unable to comply the protocol.

Minimum Eligible Age

30 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No